3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
1
Leukemia, Plasma Cell
1
Hematologic Neoplasms
1
Bronchiolitis Obliterans Syndrome
1
Interventions
fludarabine
4
Lenalidomide
4
Cyclophosphamide
4
fludarabine phosphate
3
Whole-Body Irradiation
3
Dexamethasone
3
Sirolimus
2
Mycophenolic Acid
2
venetoclax
1
sargramostim
1
plerixafor
1
pegylated granulocyte colony-stimulating factor
1
montanide ISA 51
1
itacitinib
1
isatuximab
1
incomplete Freund's adjuvant
1
ferric pyrophosphate
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
carfilzomib
1
auricularum
1
Stem Cell Transplantation
1
Specimen Handling
1
Peripheral Blood Stem Cell Transplantation
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Hyaluronoglucosaminidase
1
High-Throughput Screening Assays
1
Hematopoietic Stem Cell Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Plasma Cell
×
Budesonide
×
1 year
×
Clear all
NCT05405387
2026-06-05
IMPACT
University of Utah
Phase 2
Recruiting
120 enrolled